Comparing AMD Medications
Anti-VEGF Medications for Wet AMD
According to the AAO (2023), four anti-VEGF agents are in widespread use for wet AMD: bevacizumab (off-label), ranibizumab, aflibercept, and faricimab. All four deliver similar visual benefits in clinical studies and real-world practice. The differences that matter most to patients are injection frequency, cost, and availability.
Each medication blocks vascular endothelial growth factor (VEGF), the protein that drives abnormal blood vessel growth and leaking in wet AMD. Your retina specialist selects a medication based on your disease characteristics, insurance coverage, treatment history, and how often you can come to the office for injections.
According to the AAO (2023), aflibercept binds VEGF-A and placental growth factor (PlGF) with greater affinity than native receptors. Ranibizumab and bevacizumab bind soluble VEGF-A only. Faricimab is the first and only bispecific antibody, simultaneously neutralizing both VEGF-A and angiopoietin-2 (Ang-2), according to the FDA (2022). These mechanistic differences can matter for individual patients, including those who do not respond to one agent and may benefit from switching to another with a different target profile.
According to AAO (2023), a phase 3 comparison showed faricimab produced better anatomic responses and faster retinal fluid resolution than aflibercept 2 mg, despite equivalent vision outcomes. In the CATT trial, bevacizumab and ranibizumab showed equivalent visual acuity gains on matching schedules. These trials confirm that all four agents protect vision effectively, while individual patients may respond better to one agent over another.
Injection Frequency and Dosing Intervals
Bevacizumab and ranibizumab are typically given monthly, though both can be used with treat-and-extend or PRN protocols that allow some patients to stretch intervals to six or eight weeks. Standard aflibercept (2 mg) dosing starts monthly for three months then moves to every eight weeks. These schedules mean frequent office visits, especially in the first year of treatment.
According to AAO (2023), second-generation agents have reshaped the treatment landscape. Faricimab allows intervals of up to 16 weeks for some patients, with about 63 percent of patients treated every 16 weeks and nearly 80 percent every 12 or 16 weeks at week 112 (AAO EyeWiki, 2023). High-dose aflibercept (8 mg) can extend intervals even further, with FDA approval for dosing up to every 30 weeks in appropriate patients.
These extended-interval medications reduce the annual number of office visits and injections compared to monthly or bimonthly regimens, which can be a significant quality-of-life benefit for patients managing a chronic condition.
Your retina specialist monitors your OCT imaging at each visit and adjusts the interval based on whether your retina stays dry between injections. The longest safe interval that keeps your disease controlled is the goal. Some patients achieve extended intervals on any of the available agents, while others need frequent dosing regardless of which medication they receive.
Cost and Access
According to the AAO and NCBI Bookshelf (2023), bevacizumab costs approximately $50 to $100 per injection, making it the lowest-cost option by a wide margin. Branded agents such as ranibizumab and aflibercept cost $1,500 to $2,000 per dose. Cost-minimization analyses (Acta Ophthalmologica, 2025) suggest that high-dose aflibercept may achieve the lowest total per-patient cost over three years due to fewer injections needed, despite a higher per-dose price.
Medicare Part B covers all physician-administered anti-VEGF injections for wet AMD. Commercial and Medicare Advantage plans may have formulary preferences, prior authorization requirements, or step-therapy protocols that steer patients toward specific agents. Your retina specialist and their billing team can help you navigate coverage and find the most affordable option that still meets your clinical needs.
Biosimilars for both aflibercept and ranibizumab are now FDA-approved and available in the U.S. These products offer the same clinical benefit as the original medications at lower cost. Your retina specialist may recommend a biosimilar if your insurance favors it or if the cost savings are meaningful for your situation. Bevacizumab, already the lowest-cost option, does not have a biosimilar because its eye use is off-label.
Safety Comparison
All anti-VEGF injections carry the same rare risks: endophthalmitis, retinal detachment, and intraocular inflammation, occurring in fewer than 0.1 percent of injections. Common side effects such as temporary blurred vision, mild eye discomfort, and redness are similar across agents. These shared risks reflect the injection procedure itself rather than the specific medication.
According to Retinal Physician (2025), brolucizumab carries a documented risk of intraocular inflammation and retinal vasculitis that is higher than other agents, which affects prescribing decisions. Bevacizumab showed a slightly higher overall serious adverse event rate than ranibizumab in the CATT trial, though many of those events were non-ocular and the clinical significance is debated. Faricimab, aflibercept, and ranibizumab have comparable safety profiles in clinical trials.
Your retina specialist considers your overall health, any history of eye inflammation, and your response to prior treatments when selecting a medication. If you have had inflammation with one agent, switching to another with a different mechanism may reduce that risk. Your doctor tailors the choice to minimize side effects while maximizing disease control.
Questions About Choosing an AMD Medication
No single agent is superior for all patients. Clinical trials show similar vision outcomes across agents. The best drug for you depends on how your eye responds, how often you can visit the office, your insurance coverage, and your cost sensitivity. Your retina specialist selects the agent that offers the best balance of these factors for your situation.
Bevacizumab was developed as a cancer drug and is used off-label for wet AMD. It was never submitted for FDA approval for eye use, which means no eye-specific development costs. It is compounded from a cancer-strength vial into smaller doses, keeping the price low. Despite the cost difference, clinical trials confirm it works as well as more expensive options.
Share your preferences with your retina specialist. If cost, injection frequency, or previous experience with a specific drug influences your choice, your doctor will factor that into the decision. The final selection balances your preferences with clinical evidence and your eye's specific disease pattern.
Switching anti-VEGF agents is a common and effective strategy when your current medication no longer controls fluid on OCT imaging. Doctors may switch from one VEGF-A inhibitor to another or to a bispecific agent like faricimab. Adding photodynamic therapy or using combination approaches are also options for resistant disease.
Not entirely. Bevacizumab remains the most widely used wet AMD treatment in the U.S. due to cost. Ranibizumab retains a role for patients whose insurance covers it. Newer agents offer extended intervals for appropriate patients but do not eliminate the need for older options. Your retina specialist has a full toolkit of medications to match each patient's needs.
Cost is a legitimate factor in treatment selection. A drug you can afford to take is more effective than a premium drug you skip doses of due to expense. Your retina specialist can help you find the option that balances clinical effectiveness with financial sustainability for your situation.
Choose With Your Doctor
The right anti-VEGF medication for your wet AMD depends on your disease, your practical circumstances, and your treatment goals. Talk to your retina specialist about which agent offers the best combination of disease control, visit frequency, and affordability for you.